Celator Pharmaceuticals, a pharmaceutical company developing therapies to treat cancer, has received US patent titled, ‘Lipid Carrier Compositions with Enhanced Blood Stability’ from the US Patent and Trademark Office on 27 August 2013.
The new patent covers the company's proprietary low-cholesterol liposome compositions that are used in its two clinical stage products, CPX-351 and CPX-1, until June 2026.
These stages are based on the company's technology platform, CombiPlex.
Scientists of the pharmaceutical company have discovered that very unique properties arise when the cholesterol content ranges from 5%-20%.
They also found that the release of drugs from the liposome can be controlled to maintain the desired molar ratio.
Without the use surface-grafted polymers, the liposomes also exhibit extended blood circulation times. They have physically robust compositions that are resistant to damage from freezing and freeze-drying.
Celator Pharmaceuticals president and chief scientific officer Lawrence Mayer said that the low-cholesterol liposome technology has been instrumental in achieving the excellent biological and pharmaceutical stability features exhibited by CPX-351 and CPX-1, and has no doubt contributed to the promising clinical activity observed to date for these products.
"We look forward to further exploring the full potential of the technology and how it could possibly be applied to a wide range of drug classes and drug combinations," Mayer added.
